ArriVent BioPharma, Inc. (AVBP)
Nasdaq: AVBP · Pharmaceutical Preparations · Newtown Square, PA · filing with the SEC since 2021
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Mar 5, 2026 | Mar 3, 2025 | Mar 28, 2024 |
| Research and development | 153,351 | 79,004 | 64,884 |
| General and administrative | 24,183 | 15,304 | 9,706 |
| Total operating expenses | 177,534 | 94,308 | 74,590 |
| Operating income | -177,534 | -94,308 | -74,590 |
| Interest and investment income | 11,226 | 13,820 | 5,257 |
| Net income including non-controlling interests | -166,308 | -80,488 | -69,333 |
| Net income | -166,308 | -80,488 | -69,333 |
| Net income to common shareholders | -166,308 | -80,488 | -69,333 |
| Earnings per share, basic | -4.32 | -2.56 | -32.38 |
| Earnings per share, diluted | -4.32 | -2.56 | -32.38 |
| Weighted average shares, basic | 38,462,600 | 31,469,328 | 2,140,951 |
| Weighted average shares, diluted | 38,462,600 | 31,469,328 | 2,140,951 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeNetNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding